Will renal denervation for hypertension recover from Symplicity-3
|
Predictive Intelligence: Renal Denervation
Three of the 4 major players in the renal denervation market took big write-downs on their RDN assets after the surprise failure of Medtronic's Symplicity-3 clinical trial earlier this year.
Symplicity-3 was widely expected to be a slam dunk, vaulting Medtronic into 1st place in the U.S. renal denervation space. But the trial, more rigorously designed than previous trials with a sham control arm, failed to meet its primary efficacy endpoint.
The news ultimately prompted Medtronic to suspend further trials of the RDN technique, which uses an ablation catheter to interrupt the sympathetic nervous response that plays a role in high blood pressure. Medtronic also halted enrollment in several other trials of the Symplicity device, which the company acquired for $800 million when it bought Ardian in 2010.
In this survey, MassDevice wants you to tell us if there's any enthusiasm left for RDN in treating hypertension and, if so, which company stands to win in the RDN space.
Symplicity-3 was widely expected to be a slam dunk, vaulting Medtronic into 1st place in the U.S. renal denervation space. But the trial, more rigorously designed than previous trials with a sham control arm, failed to meet its primary efficacy endpoint.
The news ultimately prompted Medtronic to suspend further trials of the RDN technique, which uses an ablation catheter to interrupt the sympathetic nervous response that plays a role in high blood pressure. Medtronic also halted enrollment in several other trials of the Symplicity device, which the company acquired for $800 million when it bought Ardian in 2010.
In this survey, MassDevice wants you to tell us if there's any enthusiasm left for RDN in treating hypertension and, if so, which company stands to win in the RDN space.